Current management of androgenetic alopecia in men

European Journal of Dermatology

Volumn 9, Issue 8, 1999, Pages 606-609

  Wolff, Hans ^a   Kunte, Christian ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

Androgenetic alopecia; Anti androgens; Finasteride; Male pattern baldness; Minoxidil

Indexed keywords

2,4 DIAMINOPYRIMIDINE DERIVATIVE; ANTIANDROGEN; CYPROTERONE ACETATE; ESTROGEN; FINASTERIDE; MINOXIDIL; SPIRONOLACTONE; STEROID 5ALPHA REDUCTASE INHIBITOR; TESTOSTERONE;

ASTHENOSPERMIA; CLINICAL TRIAL; DRUG EFFICACY; DRUG MECHANISM; ENZYME INHIBITION; ERECTILE DYSFUNCTION; FEMALE; GYNECOMASTIA; HAIR GROWTH; HUMAN; MALE; MALE TYPE ALOPECIA; META ANALYSIS; REVIEW; SURGICAL APPROACH; VITAMIN SUPPLEMENTATION;

ALOPECIA; ANDROGEN ANTAGONISTS; HUMANS; MALE; MINOXIDIL;

EID: 0033429410     PISSN: 11671122     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (53)

1. 1. Hamilton JB. Patterned hair loss in man: types and incidence. Ann NY Acad Sci 1951; 53: 708-28.
2. 2. Ludwig E. Classification of the types of androgenetic alopecia (common baldness) arising in the female sex. Br J Dermatol 1977; 97: 249-56.
3. 3. Whiting D. Diagnostic and predictive value of sections of scalp biopsy specimens in male pattern androgenetic alopecia. J Am Acad Dermatol 1993; 28: 755-63.
4. 4. Salamon D. Genetic factors in male pattern alopecia. In: Baccaredda-Boy A, Moretti G, Frey JR, eds. Biopathology of pattern alopecia. Basel; Karger 1968: 39-56.
5. 5. Ellis JA, Stebbing M, Harrap SB. Genetic analysis of male pattern baldness and the 5-alpha-reductase genes. J Invest Dermatol 1998; 110: 849-53.
6. 6. Küster W, Happle R. The inheritance of common baldness: two B or not two B? J Am Acad Dermatol 1984; 11: 921-6.
7. 7. Sreekumar GP, Pardinas J, Wong CQ, Whiting D, Katz I, Price V, Zlotogorski A, Roberts J, Stenn K, Parimoo S. Search for male pattern baldness gene(s): hormone and chromosome 2 and 5 linkage analysis. J Invest Dermatol 1998; 110: 622 (Abstract).
8. 8. Cash TF. The psychological effects of androgenetic alopecia in men. J Am Acad Dermatol 1992; 26: 926-31.
9. 9. Wells P, Willmoth T, Russell RJH. Psychological correlates of hair loss in males. Br Psychol Rep 1995; 86: 337-44.
10. 10. Sweetman L, Surh L, Baker H, Peterson RM Nyhan WL. Clinical and metabolic abnormalities in a boy with dietary deficiency of biotin. Pediatrics 1981; 68: 553-8.
11. 11. Mock DM. Skin manifestations of biotin deficiency. Semin Dermatol 1991; 10: 296-302.
12. 12. Baumgartner ER, Suormala T. Multiple carboxylase deficiency: inherited and acquired disorders of biotin metabolism. Int J Vitam Nutr Res 1997; 57: 377-84.
13. 13. Wolf B, Heard GS, Weissbecker KA, McVoy JR, Grier RE, Leshner RT. Biotinidase deficiency: initial clinical features and rapid diagnosis. Ann Neurol 1985; 18: 614-7.
14. 14. Gupta PC, Patwari AK, Mullick DN. Alopecia with rickets: an end organ unresponsiveness to 1,25-dihydroxyvitamin D-a case report. Indian J Med Sci 1990; 44: 239-43.
15. 15. Hochberg Z, Benderli A, Levy J, Vardi P, Weisman Y, Chen T, Feldman D. 1,25-Dihydroxyvitamin D resistance, rickets, and alopecia. Am J Med 1984; 77: 805-11.
16. 16. Paus R, Schilli MB, Handjiski B, Menrad A, Henz BM, Plonka P. Topical calcitriol enhances normal hair regrowth but does not prevent chemotherapy-induced alopecia in mice. Cancer Res 1996; 56: 4438-43.
17. 17. Heidecker B, Scherrer-Hertrich B, Trueb RM. 2,4-Diamino-pyrimidin-3-oxid (Aminexil®) in der topischen Behandlung der androgenetischen Alopezie. H+G 1998; 73: 682-6.
18. 18. Ezaki T, Kasori Y. The occipito-parietal flap method in the treatment of male pattern baldness. Aesthetic Plas Surg 1995; 19: 469-72.
19. 19. Lucas MW. Recent advances in hair transplantation. Skin Pharmacol 1994; 7: 105-8.
20. 20. Dardour JC. Treatment of male pattern baldness and postoperative temporal baldness in men. Clin Plast Surg 1991; 18: 775-90.
21. 21. Ohmori K. Microsurgical free temporoparietal flaps in surgery for male pattern baldness. Clin Plastic Surg 1991; 18: 791-6.
22. 22. Epstein JS, Kabaker SS. Scolp flaps in the treatment of baldness. Long-term results. Dermatol Surg 1996; 22: 45-50.
23. 23. Buhl AE. Minoxidil's action in hair follicles. J Invest Dermatol 1991; 96: 73S-4.
24. 24. Harmon CS, Ducote J, Lutz D. Stimulation of DNA synthesis in primary mouse epidermal keratinocytes and cultured whole follicles by potassium channel openers. J Invest Dermatol 1990; 94: 533 (Abstract).
25. 25. Buhl AE, Waldon DJ, Conrad SJ, Mulholland MJ, Shull KL, Kubicek MF, Johnson GA, Brunden MN, Stefanski KJ, Stehle RG, Gadwood RC, Kamdar BV, Thomasco LM, Schostarez HJ, Schwartz TM, Diani AR. Potassium channel conductance - a mechanism affecting hair growth both in vitro and in vivo. J Invest Dermatol 1992; 98: 315-9.
26. 26. Kurata S, Uno H, Allen-Hoffmann BL. Effects of hypertrichotic agents on follicular and nonfollicular cells in vitro. Skin Pharmacol 1996; 9: 3-8.
27. 27. Wester RC, Maibach HI, Guy RH, Novak E. Minoxidil stimulates cutaneous blood flow in human balding scalps. J Invest Dermatol 1984; 82: 90-3.
28. 28. Civatte J, Laux B, Simpson NB, Vickers CF. Two percent topical minoxidil solution in male-pattern baldness: preliminary European results. Dermatologica 1987; 175 (suppl. 2): 42-9.
29. 29. Connors TJ, Cooke DE, De Launey WE, Downie M, Knudsen RG, Shumack S, Eggleston AS. Australian trial of topical minoxidil and placebo in early male pattern baldness. Australas J Dermatol 1990; 31: 17-25.
30. 30. Koperski JA, Orenberg EK, Wilkinson DI. Topical minoxidil therapy for androgenetic alopecia. A 30-month study. Arch Dermatol 1987; 123: 1483-7.
31. 31. Rietschel RL, Duncan SH. Safety and efficacy of topical minoxidil in the management of androgenetic alopecia. J Am Acad Dermatol 1987; 16: 677-85.
32. 32. Savin RC. Use of topical minoxidil in the treatment of male pattern baldness. J Am Acad Dermatol 1987; 16: 696-704.
33. 33. Karam P. Topical minoxidil therapy for androgenetic alopecia in the Middle East. The Middle-Eastern Topical Minoxidil Study Group. Int J Dermatol 1993; 32: 763-6.
34. 34. Rushton DH, Unger WP, Cotterill PC, Kingsley P, James KC. Quantitative assessment of 2% topical minoxidil in the treatment of male pattern baldness. Clin Exp Dermatol 1989; 14: 40-6.
35. 35. Olsen EA, Weiner MS, Delong ER, Pinnell S. Topical minoxidil in early male pattern baldness. J Am Acad Dermatol 1985; 113: 185-92.
36. 36. Olsen EA. Treatment of androgenetic alopecia with topical minoxidil. Res Staff Phys 1989; 35: 53-69.
37. 37. DeVillez RL. Topical minoxidil for androgenetic alopecia: optimizing the chance for success by appropriate patient selection. Dermatologica 1987; 175 (suppl. 2): 50-3.
38. 38. Hamilton JB. Male hormone stimulation is prerequisite and an incitant in common baldness. Am J Anat 1942; 71: 451-80.
39. 39. Imperato-McGinley J, Guerero L, Gautier T, Peterson RE. Steroid 5α-reductase deficiency in man: an inherited form of male pseudohermaphroditism. Science 1974; 186: 1213-5.
40. 40. Eicheler W, Dreher M, Hoffmann R, Happle R, Aumüller G. Immunohistochemical evidence for differential distribution of 5α-reductase isoenzymes in human skin. Br J Dermatol 1995; 133: 371-6.
41. 41. Lobo RA, Shoupe D, Serafini P, Brinton D, Horton R. The effects of two doses of spironolactone on serum androgens and anagen hair in hirsute women. Fertil Steril 1985; 43: 200-5.
42. 42. Weissmann A, Bowden J, Frank BL, Horwitz SN, Frost P. Antiandrogenic effects of topically applied spironolactone on the hamster flank organ. Arch Dermatol 1985; 121: 57-62.
43. 43. Takayasu S. Effect of antiandrogens on the binding of androgen to cytosol and nuclei of hamster sebaceous glands. Arch Dermatol Res 1979; 264: 49-54.
44. 44. Vermorken AJ. Reversal of androgenic alopecia by minoxidil: lack of effect of simultaneously administered intermediate doses of cyproterone acetate. Acta Derm Venereol 1983; 63: 268-9.
45. 45. Olsen EA. Androgenetic alopecia. In: Olsen EA, ed. Disorders of hair growth. McGraw-Hill Inc, 1994: 257-83.
46. 46. Orfanos CE, Vogels L. Local therapy of androgenetic alopecia with 17 alpha-estradiol. A controlled, randomized double-blind study. Dermatologica 1980; 161: 124-32.
47. 47. Suddoth SL, Koronkowski MJ. Finasteride: the first 5α-reductase inhibitor. Pharmacotherapy 1993; 13: 309-25.
48. 48. Spinucci G, Pasquali R. Finasteride: a new drug for the treatment of male hirsutism and androgenetic alopecia? Clin Ther 1996; 147: 305-15.
49. 49. Gormley GJ. Finasteride: a clinical review. Biomed Pharmacother 1995; 49: 319-24.
50. 50. Rhodes L, Harper J, Uno H, Gaito G, Audette-Arruda J, Kurata S, Berman C, Primka R, Pikounis B. The effects of finasteride (Proscar) on hair growth, hair cycle stage, and serum testosterone and dihydrotestosterone in adult male and female stumptail macaques (Macaca arctoides). J Clin Endocrinol Metab 1994; 79: 991-6.
51. 51. Dallob AL, Sadick NS, Unger W, Lipert S, Geissler LA, Gregoire SL, Nguyen HH, Moore EC, Tanaka WK. The effect of finasteride, a 5α-reductase inhibitor, on scalp skin testosterone and dihydrotestosterone concentrations in patients with male pattern baldness. J Clin Endocrinol Metab 1994; 79: 703-6.
52. 52. Peters DH, Storkin EM. Finasteride: a review of its potential on the treatment of benign prostatic hyperplasia. Drugs 1993; 46: 177-208.
53. 53. Kaufman KD, Olsen EA, Whiting D, Savin R, DeVillez R, Bergfeld W, Price VH, Van Neste D, Roberts JL, Hordinsky M, Shapiro J, Binkowitz B, Gormley GJ and the Finasteride Male Pattern Hair Loss Study Group. Finasteride in the treatment of men with androgenetic alopecia (male pattern hair loss). J Am Acad Dermatol 1998; 36: 578-89.